OurView Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A clear price is useful evidence about an offer, but it is not evidence that the treatment behind that offer matches a studied medicine. OurView illustrates that distinction. Its website advertises compounded semaglutide and tirzepatide, clinician-guided care, free shipping and prices that do not increase with the prescribed dose. Those are concrete commercial commitments worth examining. They do not, by themselves, establish the formulation a patient will receive, the quality of follow-up or the results that patient should expect.

This review examines OurView’s public documentation consulted October 19, 2026, separating advertised services, contractual conditions and independent clinical context. OurView describes itself as a patient management platform, not the direct provider of medical or pharmacy services. That division matters throughout the experience: an independent clinician determines treatment, a pharmacy compounds and dispenses medication, and the platform manages access and purchasing. The central question is how clearly those responsibilities—and the evidence behind the treatment—are documented before someone pays.

At a glance

Service model: OurView says it connects patients with independent licensed physician networks and a licensed U.S. pharmacy; it does not directly provide medical or pharmacy services.
Sources: [7]
Compounded semaglutide pricing: $109 monthly or $297 prepaid for three months, equivalent to $99 per month; advertised at any prescribed dose, with no membership fee and free shipping.
Sources: [7]
Compounded tirzepatide pricing: $129 monthly or $357 prepaid for three months, equivalent to $119 per month; advertised at any prescribed dose, with no membership fee and free shipping.
Sources: [7]
Prescription decision: Payment does not guarantee that a prescription will be written or dispensed. An independent provider reviews eligibility and determines the plan.
Sources: [7] [5]
Cancellation boundary: The policy permits subscription cancellation through the portal before shipment and says sales are final once payment is charged and the package is handed to the carrier.
Sources: [6]

Start with the product, not the ingredient name

OurView’s commercial listings specifically identify compounded semaglutide and compounded tirzepatide. That wording is more consequential than the familiar ingredient names. FDA explains that compounded preparations are not FDA approved and do not undergo its premarket review for safety, effectiveness and quality. Approval belongs to a particular drug product, not to a platform or pharmacy. OurView’s educational material acknowledges that compounded medications generally are not reviewed or approved by FDA; it does not establish approval for the preparations advertised here.

Nonapproval alone does not demonstrate clinical inequivalence, nor does it settle whether a particular prescription is appropriate. FDA recommends compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. The useful next question is therefore specific: what preparation is proposed, and why does it address the patient’s medical needs? Our guide to approved medicines and compounded preparations explains why those are separate evidence questions.

The consulted commercial pages do not confirm the plans’ administration route, concentration, dispensed quantity or included administration supplies. An educational article mentions oral and sublingual formulations as discussion options, but that passage does not establish that OurView sells them. Readers should not assume an injectable, oral or sublingual product based on general educational language. A product-specific description is needed before evaluating how closely any research applies.

Sources: [7] [9] [1]

The advertised prices are concrete, but the billing picture is incomplete

OurView offers a genuine choice between monthly payment and three-month prepayment. Compounded semaglutide is advertised at $109 monthly or $297 prepaid for three months. Compounded tirzepatide is $129 monthly or $357 prepaid for three months. The lower $99 and $119 monthly equivalents require that three-month prepayment; they are not separate monthly payment options. OurView advertises a $30 saving on each prepaid option, no membership fee, free shipping and the same price at any prescribed dose.

Those statements help distinguish dose-based pricing from payment frequency, but they do not document every financial responsibility. The reviewed pages do not establish dispensed quantities, whether administration supplies are included, or a complete list of potentially separate charges. Nor does a three-month package establish a minimum commitment or a particular shipment schedule. The terms also allow correction of an incorrectly displayed price, leaving the customer to accept the corrected price or decline the transaction.

Insurance language deserves separate attention. OurView says its services are not health insurance or a substitute for it. Its terms require customers not to submit claims for the telemedicine services to Medicare or other federal, state or private payers. That is a telemedicine-claim restriction, not confirmation of how medication insurance claims are handled. The documentation does not confirm medication coverage, HSA/FSA acceptance, automatic-renewal mechanics or the date of subsequent charges.

OurView’s advertised payment options and their boundaries
Offer	Advertised charge	Important qualification
Compounded semaglutide, monthly	$109 per month	Any prescribed dose; no membership fee; free shipping
Compounded semaglutide, three months	$297 prepaid	$99 monthly equivalent; three-month prepayment required
Compounded tirzepatide, monthly	$129 per month	Any prescribed dose; no membership fee; free shipping
Compounded tirzepatide, three months	$357 prepaid	$119 monthly equivalent; three-month prepayment required
Initial assessment	Advertised as free	No commitment; payment does not guarantee a prescription

Sources: [7] [8]

Who evaluates the patient—and who can decline treatment

OurView describes a process in which a prospective patient chooses a treatment area, answers health and treatment questions, and receives review by a licensed provider who determines eligibility and the treatment plan. The initial assessment is advertised as free, with no commitment or contract. The claim that getting started takes about three minutes concerns the beginning of that process. It is not a documented clinical-review deadline, prescription approval time or delivery estimate.

The prescribing decision remains independent of payment. OurView explicitly says paying does not guarantee a prescription will be written or dispensed. Its terms permit a provider to decline care when, in that provider’s professional judgment, services would not be medically or ethically appropriate, including possible misuse. The consulted pages do not name the clinical networks or treating professionals, identify individual licenses, or provide complete eligibility criteria, laboratory requirements or consultation modality.

Access boundaries are only partly documented. The terms require users to be at least 18, while also addressing a parent or guardian’s use on behalf of a minor; that provision does not establish pediatric GLP-1 eligibility. Services are intended for residents of the United States and its territories, excluding residents elsewhere. However, there is no confirmed state-by-state availability list. A pharmacy’s advertised nationwide reach cannot establish that an appropriately authorized clinician is available to every prospective patient.

Sources: [7] [5] [8]

The pharmacy relationship needs product-level clarification

OurView says a licensed pharmacy partner compounds and dispenses medication, and expressly states that OurView itself is neither a state-licensed pharmacy nor a manufacturer. Its commercial explanation attributes its pricing to working directly with a licensed, nationwide pharmacy. These are provider statements, not independent license verification. The commercial page does not identify that pharmacy by name, leaving readers unable to connect the advertised GLP-1 offer to a specific dispensing entity from that page alone.

The returns policy lists Boudreaux’s New Drug Store at 404 East Prien Lake Road in Lake Charles, Louisiana. That is a documented return address, not proof that this pharmacy prepares or dispenses every GLP-1 prescription obtained through OurView. Before purchasing, a useful clarification is the name and contact information of the pharmacy responsible for the particular prescription, together with the preparation’s route, concentration, labeling, included supplies and storage instructions.

The terms also permit patients to request a pharmacy of their choosing by emailing service@ourviewhealth.com before completing the order. That option should not be read as a guarantee that OurView’s advertised prices, shipping arrangements or preparation availability transfer to another pharmacy. The consulted terms do not explain those consequences. This is a concrete example of why public provider documentation can establish that an option exists without resolving how it will work for an individual order.

Sources: [5] [8] [6]

Clinical studies do not measure OurView’s performance

Semaglutide and tirzepatide have been studied in randomized trials, but the distinction between an ingredient’s research history and a platform’s performance remains essential. STEP 1 studied subcutaneous semaglutide in adults without diabetes over 68 weeks, with lifestyle intervention in both groups; Novo Nordisk funded it. SURMOUNT-1 studied subcutaneous tirzepatide in adults without diabetes over 72 weeks and was funded by Eli Lilly. Neither was a trial of OurView or its compounded preparations.

Those studies therefore cannot establish OurView-specific weight loss, tolerability, retention or service quality. Their findings also do not automatically transfer to different routes, microdoses or blends. Gastrointestinal adverse effects and treatment discontinuation were part of the trial evidence, not details to omit when discussing benefits. Our explanation of why a clinical trial is not a company performance report addresses this recurring gap between research and marketing.

The consulted OurView pages do not establish measured outcomes for its own patients or provide comparative evidence for its advertised preparations. Testimonials and promotional comparisons cannot fill that gap. This does not prove the service is ineffective; it limits what can responsibly be concluded from the available documentation. The most defensible assessment is that OurView documents an access and purchasing model more clearly than it documents product-specific clinical performance.

Sources: [7] [9] [3] [4]

Ongoing support is promised without a defined schedule

OurView advertises ongoing dosage adjustments as the patient responds, with no extra charge and no extra appointments for those adjustments. It also says a care team is available for questions about medication or progress. These are meaningful service claims, but they are not a complete follow-up protocol. The pages do not specify scheduled review frequency, support hours, response-time targets, clinician continuity or how a patient moves from a routine question to an urgent clinical concern.

The distinction matters because follow-up involves more than continued access to medication. NIDDK describes medication decisions as involving benefits, side effects, health conditions, other medicines and costs, with ongoing attention to response and tolerability. OurView’s adjustment promise should therefore prompt questions about who reviews symptoms, which communication channel reaches a clinician and when another appointment may be necessary. The advertised no-extra-charge adjustment language does not establish that every possible additional service is included.

OurView also describes SMS prescription updates, refill reminders, medication notifications and health alerts. Texting STOP ends that SMS service; it is not documented as a way to cancel treatment. The terms warn that email and text are not secure communication methods and may be read by unauthorized parties. Patients should identify the appropriate clinical channel rather than assume every reminder can support a confidential consultation. Our guide to clinical follow-up develops those practical distinctions.

Sources: [5] [8] [2]

Free shipping is documented; arrival conditions are not

OurView advertises free shipping, discreet packaging and fast home delivery. The consulted pages do not give numerical deadlines for clinical review, pharmacy preparation, dispatch or arrival. They also do not specify transport-temperature requirements for the advertised preparations. These omissions matter when planning around a delivery, but they should not be converted into assumptions about actual shipping performance. A general promise of speed does not identify when a particular prescription will reach the patient.

The returns policy provides more detail about disrupted shipments. Patients whose medication arrives damaged or is lost in transit are instructed to contact patient care. For a lost package, OurView says it will first work with the carrier to locate or redirect it and will reship the order if lost. The policy does not specify a replacement deadline or an equally definite remedy for damaged medication. Carrier handoff is also a sales-finality trigger, not evidence that delivery has occurred.

For an injectable GLP-1 product that arrives warm or inadequately refrigerated, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy. That guidance is general regulatory context, not a finding that OurView has had such deliveries. Order or product problems can be raised at service@ourviewhealth.com or (573) 685-6155. Those published contact paths are useful, although the documentation does not establish their operating hours or response speed.

Sources: [7] [5] [6] [1]

Cancellation is not the same as recovering a payment

OurView’s weight-loss page advertises no contracts and cancellation at any time. Its operational policy says patients can use patient.ourviewhealth.com before products ship to change their address, payment method or subscription status. The same policy says all sales are final once payment has been charged and the package handed to the carrier. Read together, these statements support a way to stop a subscription, not an unrestricted right to recover money already collected.

The documentation leaves important situations unresolved: the treatment of an unused portion of a three-month prepayment, the refund outcome if care is denied or no prescription is issued, and the precise renewal schedule. OurView states that prescription medication cannot be returned after dispensing, attributing that restriction to state and federal regulations. Separately, unopened nonprescription items may be accepted within 30 days of sale, with return shipping paid by the patient. That limited policy should not be applied to prescription GLP-1 medication.

The terms add another point to clarify: the arbitration clause specifies San Diego and California law, while the general governing-law clause identifies Georgia. This documentary inconsistency is not a conclusion about enforceability. More immediately useful before payment is written confirmation of the next charge date, how to stop it, and what happens to any prepaid balance. Those answers would make OurView’s accessible pricing easier to evaluate alongside the actual financial commitment.

Sources: [5] [6] [8]

Questions & answers

Does OurView directly prescribe and compound the medication?

No. OurView describes itself as a patient management platform partnering with independent physician networks and a licensed U.S. pharmacy. It says independent providers deliver medical services and a pharmacy partner compounds and dispenses medication. The consulted pages do not identify the treating networks or establish which pharmacy handles every GLP-1 prescription. Ask for the responsible clinician and dispensing pharmacy before treatment begins.

Sources: [7] [5]

Can I pay $99 or $119 one month at a time?

Not under the advertised options. The $99 semaglutide and $119 tirzepatide figures are monthly equivalents of $297 and $357 prepaid three-month plans. Separate monthly options are advertised at $109 and $129, respectively. Both products are compounded, and OurView advertises any prescribed dose, no membership fee and free shipping. The pages do not establish a price guarantee for future periods.

Sources: [7] [8]

Does the free assessment guarantee that I can receive treatment?

No. OurView advertises a free, no-commitment assessment, followed by provider review of eligibility and the treatment plan. It expressly states that payment does not guarantee a prescription will be written or dispensed. Complete clinical criteria and state availability are not documented in the consulted pages. The refund outcome when care is denied or no prescription is issued also needs clarification before payment.

Sources: [5] [7] [8]

Can I use a pharmacy other than OurView’s preferred partner?

The terms say patients may direct a prescription to a pharmacy of their choosing by emailing service@ourviewhealth.com before completing the order. They do not explain whether the advertised bundled pricing or free shipping applies through that alternative channel. Confirm the receiving pharmacy’s ability to fill the prescription, its price and the division of support responsibilities rather than assuming the standard offer transfers unchanged.

Sources: [8] [7]

What happens if my medication is lost, damaged or arrives warm?

OurView directs patients to its care team for damaged or lost medication. For lost shipments, it says it will work with the carrier to locate or redirect the package and reship if lost; a specific damaged-product remedy is not documented. Separately, FDA advises not using injectable GLP-1 medication that arrives warm or insufficiently refrigerated and contacting the provider or dispensing pharmacy. OurView publishes service@ourviewhealth.com and (573) 685-6155 for order problems.

Sources: [6] [1]

Does canceling return the unused part of a prepaid plan?

The consulted policy does not answer that question. It permits portal cancellation before shipment and declares sales final after payment and carrier handoff. Those provisions do not establish a prorated refund for a prepaid three-month plan. Obtain the applicable cancellation and refund terms in writing before choosing prepayment. Texting STOP only ends SMS notifications; it is not documented as canceling the treatment subscription.

Sources: [6] [8] [7]

Our assessment

OurView’s strongest documentary feature is its relatively explicit commercial offer: named compounded ingredients, monthly and prepaid alternatives, dose-independent advertised pricing, no membership fee and free shipping. It also acknowledges that prescribing and pharmacy work belong to independent parties. The evidence is less complete where treatment becomes product-specific: route, concentration, dispensing pharmacy, clinical criteria, follow-up timing and measured outcomes. Renewal and prepaid-refund questions remain consequential gaps. These limitations do not establish poor care or ineffective treatment, but they prevent a stronger clinical conclusion. Before paying, seek a written product description, identification of the responsible clinician and pharmacy, a clear follow-up pathway, and the cancellation and refund rules for the selected payment option.

Visit OurView’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

OurView Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the product, not the ingredient name

02The advertised prices are concrete, but the billing picture is incomplete

03Who evaluates the patient—and who can decline treatment

04The pharmacy relationship needs product-level clarification

05Clinical studies do not measure OurView’s performance

06Ongoing support is promised without a defined schedule

07Free shipping is documented; arrival conditions are not

08Cancellation is not the same as recovering a payment